Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer

Nuclear Medicine Communications

Volumn 35, Issue 1, 2014, Pages 20-29

  Challapalli, Amarnath ^a   Barwick, Tara ^b   Tomasi, Giampaolo ^a   O'Doherty, Michael ^c   Contractor, Kaiyumars ^a   Stewart, Simon ^a   Al Nahhas, Adil ^b   Behan, Kevin ^a   Coombes, Charles ^a   Aboagye, Eric O ^a   Mangar, Stephen ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

11C choline PET CT; Androgen deprivation; Imaging biomarker; Prostate cancer; Radiotherapy

Indexed keywords

CHOLINE C 11; PROSTATE SPECIFIC ANTIGEN; ANDROGEN; CARBON; CHOLINE; DIAGNOSTIC AGENT;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CHOLINE UPTAKE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEASIBILITY STUDY; GLUTEUS MAXIMUS MUSCLE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET SCANNER; PROSTATE CANCER; RADIOACTIVITY; TREATMENT RESPONSE; TUMOR VOLUME; ADJUVANT THERAPY; COMPUTER ASSISTED TOMOGRAPHY; METABOLISM; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; TIME; TREATMENT OUTCOME;

ANDROGENS; CARBON RADIOISOTOPES; CHOLINE; HUMANS; MALE; MULTIMODAL IMAGING; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84889243759     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0000000000000014     Document Type: Article

References (35)

1. Zeisel SH. Dietary choline: biochemistry, physiology, and pharmacology. Annu Rev Nutr 1981; 1:95-121.
2. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer 2011; 11:835-848.
3. 11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. Clin Cancer Res 2011; 17:7673-7683.
4. Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol 2013; 31: 427-435.
5. Picchio M, Castellucci P. Clinical indications of C-choline PET/CT in prostate cancer patients with biochemical relapse. Theranostics 2012; 2:313-317.
6. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease. Actas Urol Esp 2011; 35:501-514.
7. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68. Gy of radiotherapy with 78 Gy. J Clin Oncol 2006; 24:1990-1996. (Pubitemid 46622106)
8. Westphalen AC, McKenna DA, Kurhanewicz J, Coakley FV. Role of magnetic resonance imaging and magnetic resonance spectroscopic imaging before and after radiotherapy for prostate cancer. J Endourol 2008; 22:789-794. (Pubitemid 351550760)
9. Barrett T, Gill AB, Kataoka MY, Priest AN, Joubert I, McLean MA, et al. DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: a feasibility study. Magn Reson Med 2012; 67:778-785.
10. Valentini AL, Gui B, D'Agostino GR, Mattiucci G, Clementi V, Di Molfetta IV, et al. Locally advanced prostate cancer: three-dimensional magnetic resonance spectroscopy to monitor prostate response to therapy. Int J Radiat Oncol Biol Phys 2012; 84:719-724.
11. 11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res 2011; 17:3751-3759.
12. Van den Bergh L, Koole M, Isebaert S, Joniau S, Deroose CM, Oyen R, et al. Is there an additional value of (1)(1)C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules? Int J Radiat Oncol Biol Phys 2012; 83:1486-1492.
13. 11C]choline. J Labelled Compounds Radiopharm 2000; 43:195-203. (Pubitemid 30072211)
14. 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging 2005; 32: 742-748. (Pubitemid 41125415)
15. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med 2009; 50 (Suppl 1):11S-20S.
16. 11C]Choline positron emission tomography in estrogen receptorpositive breast cancer. Clin Cancer Res 2009; 15:5503-5510.
17. 18F]fluorothymidine PET data. EJNMMI Res 2012; 2:11.
18. Mankoff DA, Shields AF, Graham MM, Link JM, Krohn KA. A graphical analysis method to estimate blood-to-tissue transfer constants for tracers with labeled metabolites. J Nucl Med 1996; 37:2049-2057. (Pubitemid 26428380)
19. 11C]choline; implications for in vivo imaging with positron emission tomography. Eur J Nucl Med 2000; 27: 25-32. (Pubitemid 30097256)
20. 11C-labeled choline analogs for cancer detection by positron emission tomography. Clin Cancer Res 2012; 18:1063-1072.
21. 11C] choline PET/CT. Clin Nucl Med 2010; 35:701-703.
22. 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001; 61:110-117. (Pubitemid 32095708)
23. 11C- choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging 2011; 38:1985-1989.
24. Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C, et al. [(11)C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and antiandrogenic therapy. Eur J Nucl Med Mol Imaging 2008; 35:1065-1073.
25. 11C]choline? Eur J Nucl Med Mol Imaging 2011; 38:1964-1966.
26. Hanlon AL, Pinover WH, Horwitz EM, Hanks GE. Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys 2001; 50: 845-849. (Pubitemid 32594825)
27. Buyyounouski MK. Radiotherapy: PSA nadir predicts long-term mortality. Nat Rev Clin Oncol 2010; 7:188-190.
28. Collette L, Burzykowski T, Schroder FH. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer 2006; 42:1344-1350. (Pubitemid 43922404)
29. Jadvar H. Can choline PET tackle the challenge of imaging prostate cancer? Theranostics 2012; 2:331-332.
30. Casamassima F, Masi L, Menichelli C, Bonucci I, Casamassima E, Lazzeri M, et al. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori 2011; 97:49-55.
31. Greven KM, Williams DW 3rd, Keyes JW Jr., McGuirt WF, Watson NE Jr., Randall ME, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 1994; 74:1355-1359. (Pubitemid 24301792)
32. Rodemann HP, Blaese MA. Responses of normal cells to ionizing radiation. Semin Radiat Oncol 2007; 17:81-88. (Pubitemid 46467380)
33. 18F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum 2003; 48:3077-3084. (Pubitemid 37409318)
34. 11C-choline PET/CT using multimodality fusion techniques. J Nucl Med 2009; 50:1585-1593.
35. NICE. Prostate cancer: diagnosis and treatment; 2008. Available at: http://publications.nice.org.uk/prostate-cancer-cg58. [Accessed 1 October 2012].